Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SKI-G-801 monotherapy in advanced solid tumors
NCT05971862Phase 1Active, not recruiting
- Sponsor
- Oscotec Inc.
- Start
- Jan 2022
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of denfivontinib in solid tumor (6 cohorts), sponsored by Oscotec Inc. Primary endpoints: Maximum Tolerated Dose and/or Recommended Phase 2 Dose, Number of treatment discontinuation or dose reduction and 2 more. Started Jan 2022; status: active, not recruiting.
02
Drugs
denfivontinib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05971862.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05971862.